This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands
by Zacks Equity Research
OPKO Health reports wider-than-expected second-quarter 2025 loss and revenue decline, but gross margin expands and product sales remain stable.
TMDX Stock Gains Post Q2 Earnings & Revenue Beat, Margins Up
by Zacks Equity Research
TransMedics stock jumps 10.5% as Q2 EPS beats by 91.7%, revenue rises 37.7%, and operating margin expands 1230 basis points.
Teladoc Health Q2 Loss Narrower Than Expected on Declining Expenses
by Zacks Equity Research
TDOC posts narrower Q2 loss and trims costs, but shares dip as U.S. revenues and visit volumes decline.
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised
by Zacks Equity Research
Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
CONMED Q2 Earnings & Revenues Beat Estimates, 2025 Outlook Raised
by Zacks Equity Research
CNMD reports solid second-quarter results, driven by improving sales across both segments.
Merit Medical Q2 Earnings Beat Estimates, Gross Margin Expands
by Zacks Equity Research
MMSI beats second-quarter 2025 earnings estimates as gross margin expands and strong U.S. and Cardiovascular sales drive revenue growth.
GE HealthCare Q2 Earnings & Sales Beat Estimates, Net Margin Rises
by Zacks Equity Research
GEHC's second-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves with better pricing.
Wall Street Analysts Think West Pharmaceutical (WST) Could Surge 25.26%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 25.3% upside potential for West Pharmaceutical (WST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Ecolab Stock Down in Pre-Market Post Q2 Earnings Miss, Margins Expand
by Zacks Equity Research
ECL stock dips in pre-market despite second-quarter 2025 earnings growth and margin expansion, as EPS misses estimates by a penny.
UnitedHealth Q2 Earnings Miss Estimates on Increasing Medical Costs
by Zacks Equity Research
UNH misses Q2 earnings estimates as surging medical costs slash EPS 40%, despite revenue growth and Optum Rx strength.
Universal Health Q2 Earnings Beat on Strong Acute Care Admissions
by Zacks Equity Research
UHS tops Q2 estimates with EPS up 24% as strong acute care and behavioral admissions drive revenue growth.
West Pharmaceutical (WST) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
West Pharmaceutical (WST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for July 28th
by Zacks Equity Research
CALX, MEDP and WST made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 28, 2025.
WST Stock Rises on Q2 Earnings Beat, EPS View Up on Tariff & FX Benefit
by Zacks Equity Research
West Pharmaceutical's second-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.
West Pharmaceutical Services (WST) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of +21.85% and +5.39%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
WST Q2 Earnings Preview: Will the Stock's Segmental Edge Hold Up?
by Zacks Equity Research
West Pharmaceutical targets steady Q2 growth as high-value GLP-1 and SmartDose demand drives segment momentum.
WST Stock Builds on GLP-1 Growth, Annex 1 and Margins in Focus
by Zacks Equity Research
West Pharmaceutical Services rides on GLP-1 demand and Annex 1 expansion, but margins face pressure from pricing and tariff headwinds.
Wall Street Analysts Believe West Pharmaceutical (WST) Could Rally 26.92%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for West Pharmaceutical (WST) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why Is Labcorp (LH) Up 2.5% Since Last Earnings Report?
by Zacks Equity Research
Labcorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
West Pharmaceutical (WST) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does West Pharmaceutical (WST) Have the Potential to Rally 31.09% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 31.1% in West Pharmaceutical (WST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
WST Stock Rises on Q1 Earnings Beat, EPS View Up on Tariff & FX Benefit
by Zacks Equity Research
West Pharmaceutical's first-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.
West Pharmaceutical Services (WST) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 18.85% and 1.68%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Segmental Performance Drive West Pharmaceutical's Q1 Earnings?
by Zacks Equity Research
West Pharmaceutical Services' first-quarter results are likely to reflect growth amid pharma stabilization, biologics rebound & contract manufacturing gains.
Earnings Preview: West Pharmaceutical Services (WST) Q1 Earnings Expected to Decline
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.